ARTICLE | Company News
Aventis licenses Ajinomoto cancer compound
July 12, 2001 7:00 AM UTC
Aventis Pharma (AVE) received exclusive worldwide rights to Ajinomoto's AVE8062 anti-angiogenic compound (formerly known as AC-7700), in exchange for milestones and royalties. AVE expects to begin hum...